Constantinos Yiangou

TL;DR: Sentinel lymph node biopsy is associated with reduced arm morbidity and better quality of life than standard axillary treatment and should be the treatment of choice for patients who have early-stage breast cancer with clinically negative nodes.

TL;DR: It is suggested that up-regulation of resistance genes or down-regulation in target genes may occur rapidly in human solid tumors, within days of the start of treatment, and that similar changes are present in pre- and post-chemotherapy biopsy material.

TL;DR: SLN biopsy accurately staged the axilla in male breast cancer patients and should be considered for axillary staging in male Breast cancer patients with clinically negative axillae.

TL;DR: After 2 years following the diagnosis of breast cancer there is no evidence to support the view that regular clinical review improves psychological morbidity or quality of life, and point of need access is acceptable to the majority of patients.

TL;DR: Intraoperative assessment of SLNs in breast cancer using a molecular assay is a safe, acceptable and accurate technique that allows a reduction in the frequency of delayed axillary clearance surgery.